Search Results - "Latreille, Mathilde"

Immunogenicity and safety of the Southern Hemisphere 2015 formulation of Vaxigrip by Latreille-Barbier, Mathilde, Rouzier, Regine, Astruc, Beatrice, Lavis, Nathalie, Donazzolo, Yves

“…An inactivated split-virion trivalent influenza vaccine (IIV3; Vaxigrip®, Sanofi Pasteur) has been available globally since 1968. Here, we describe the results…”
Get full text

Immunogenicity and Safety of a Purified Vero Rabies Vaccine—Serum Free, Compared With 2 Licensed Vaccines, in a Simulated Rabies Post-Exposure Regimen in Healthy Adults in France: A Randomized, Controlled, Phase 3 Trial by Pineda-Peña, Andrea-Clemencia, Jiang, Qian, Petit, Celine, Korejwo-Peyramond, Joanna, Donazzolo, Yves, Latreille, Mathilde, Homery, Marie-Claude, Babin, Valerie, Benamor, Sonia, Pichon, Sylvie, Guinet-Morlot, Françoise, Minutello, Ada-Maria

“…Abstract Background A next-generation Vero cell rabies vaccine (PVRV-NG2) was developed using the same Pitman–Moore strain as in the licensed purified Vero…”
Get full text

Determination of the Optimal Single Dose Treatment for Acoziborole, a Novel Drug for the Treatment of Human African Trypanosomiasis: First-in-Human Study by Tarral, Antoine, Hovsepian, Lionel, Duvauchelle, Thierry, Donazzolo, Yves, Latreille, Mathilde, Felices, Mathieu, Gualano, Virginie, Delhomme, Sophie, Valverde Mordt, Olaf, Blesson, Severine, Voiriot, Pascal, Strub-Wourgaft, Nathalie

“…Background and Objectives Acoziborole is a novel boron-containing candidate developed as an oral drug for the treatment of human African trypanosomiasis (HAT)…”
Get full text

Evaluation of the Effects of Therapeutic and Supratherapeutic Doses of Agomelatine on the QT/QTc Interval: A Phase I, Randomized, Double-blind, Placebo-controlled and Positive-controlled, Crossover Thorough QT/QTc Study Conducted in Healthy Volunteers by Donazzolo, Yves, Latreille, Mathilde, Caillaud, Marie-Anne, Mocaer, Elisabeth, Seguin, Laure

“…The effects of the antidepressant agomelatine up to a supratherapeutic dose (400 mg, single dose) on the QT corrected (QTc) interval were assessed in a…”
Get full text

Translation of TRO40303 from myocardial infarction models to demonstration of safety and tolerance in a randomized Phase I trial by Le Lamer, Sophie, Paradis, Stéphanie, Rahmouni, Hidayat, Chaimbault, Corinne, Michaud, Magali, Culcasi, Marcel, Afxantidis, Jean, Latreille, Mathilde, Berna, Patrick, Berdeaux, Alain, Pietri, Sylvia, Morin, Didier, Donazzolo, Yves, Abitbol, Jean-Louis, Pruss, Rebacca M, Schaller, Sophie

“…Although reperfusion injury has been shown to be responsible for cardiomyocytes death after an acute myocardial infarction, there is currently no drug on the…”
Get full text

Effects of 28-day Bifidobacterium animalis subsp. lactis HN019 supplementation on colonic transit time and gastrointestinal symptoms in adults with functional constipation: A double-blind, randomized, placebo-controlled, and dose-ranging trial by Ibarra, Alvin, Latreille-Barbier, Mathilde, Donazzolo, Yves, Pelletier, Xavier, Ouwehand, Arthur C.

“…Bifidobacterium animalis subsp. lactis HN019 (HN019) ameliorates chronic idiopathic constipation. Our aim was to determine the efficacy and safety of 28-day…”
Get full text

Evaluation of performance, safety, subject acceptance, and compliance of a disposable autoinjector for subcutaneous injections in healthy volunteers by Berteau, Cecile, Schwarzenbach, Florence, Donazzolo, Yves, Latreille, Mathilde, Berube, Julie, Abry, Herve, Cotten, Joël, Feger, Celine, Laurent, Philippe E

“…A disposable autoinjector was developed for subcutaneous (SC) self-injection by patients with chronic diseases. To verify its performance and evaluate its…”
Get full text

Effects of 28-Day Bifidobacterium animalis subsp. lactis HN019 Supplementation on Colonic Transit Time and Gastrointestinal Symptoms in Adults With Functional Constipation: 459 by Ibarra, Alvin, Latreille-Barbier, Mathilde, Donazzolo, Yves, Pelletier, Xavier, Ouwehand, Arthur

Get full text

Immunogenicity and safety of the Southern Hemisphere 2015 formulation of Vaxigrip by Latreille-Barbier, Mathilde, Rouzier, Regine, Astruc, Beatrice, Lavis, Nathalie, Donazzolo, Yves

“…An inactivated split-virion trivalent influenza vaccine (IIV3; Vaxigrip®, Sanofi Pasteur) has been available globally since 1968. Here, we describe the results…”
Get full text